Skip to content
Tech News
← Back to articles

Publisher Correction: GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice

read original get GLP-1R GIPR PPAR Agonist → more articles
Why This Matters

This correction highlights the ongoing advancements in multi-target drug development for obesity and diabetes, emphasizing the potential of complex receptor agonists to improve treatment outcomes. Such innovations could lead to more effective therapies, benefiting millions of patients worldwide. Staying updated on these developments is crucial for the tech industry and healthcare providers aiming to integrate cutting-edge solutions.

Key Takeaways

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions